Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study
December 10, 2025 Johannes Jungwirth, Samuel Westenhöfer, Helena Aicher et al.
In a real-world clinical setting in Switzerland, 19 patients with treatment-resistant depression received one to four doses of psilocybin (20–35 mg). Depression severity, measured by the Montgomery–Åsberg Depression Rating Scale and the Beck Depression Inventory II, showed significant and clinically meaningful reductions from before to after treatment. Response rates were 33.3% and remission rates 22.2% on one scale; on the other, both were 27.8%. No serious adverse events occurred, and multiple dosing did not add benefit. These response and remission rates are lower than those seen in earlier controlled trials, but the findings provide some of the first real-world evidence for psilocybin's antidepressant effects.